Our Science
microRNA: A Molecular Window into Brain Injury
MicroRNAs are small, non-coding RNA molecules that regulate gene expression and may be released into the bloodstream following cellular injury. GLIA Diagnostics has clinically studied a panel of miRNAs as potential biomarkers for TBI — offering a molecular signal that may complement existing clinical assessment tools.
What Is microRNA?
MicroRNAs (miRNAs) are short non-coding RNA molecules, typically around 18–25 nucleotides in length. They do not encode proteins; instead, they regulate gene expression by binding to messenger RNA (mRNA) targets and modulating their translation. miRBase v22 contains 2,654 annotated mature human miRNA sequences, each with specific tissue expression patterns and regulatory roles.
Following cellular injury or death, intracellular miRNAs can be released into the extracellular space and enter the bloodstream, where they circulate in a relatively stable form — protected from degradation by encapsulation in exosomes, microvesicles, and protein complexes. Circulating miRNAs can remain stable in blood, with temporal profiles varying by the individual miRNA, injury characteristics and sampling time. This stability makes circulating miRNAs candidates for blood-based diagnostic biomarkers with potential utility across both acute and subacute assessment windows.
Neural miRNA Expression
Why GLIA Is Investigating Neural miRNAs for TBI?
The brain expresses a distinct set of miRNAs that are enriched in neural and glial tissue relative to many other organs. When neurons or astrocytes are damaged — as may occur in TBI — these miRNAs may be released into the cerebrospinal fluid and subsequently into the peripheral bloodstream. Their detection in blood may therefore provide a tissue-associated signal of brain injury, though the degree of specificity requires further analytical and clinical validation.
GLIA Diagnostics has clinically studied a panel of miRNAs as potential TBI biomarkers. The research suggests these miRNAs may offer complementary biological information to existing protein biomarkers such as GFAP and UCH-L1, which have established acute utility and are FDA-cleared for use in adults with suspected mTBI. GLIA's miRNA panel is under ongoing development and requires further analytical and clinical validation before any clinical diagnostic use.
The miRNA Research Landscape
2,654
annotated mature human miRNA sequences in miRBase v22, each with tissue-specific expression patterns
18–25 nt
typical length of a microRNA molecule — small enough to be encapsulated and protected in exosomes for stability in blood
Variable
temporal profiles — circulating miRNAs can remain stable in blood, with detection windows varying by individual miRNA, injury characteristics and sampling time
Panel
approach — a combination of miRNAs may provide complementary biological information relevant to injury response, prognosis and longitudinal recovery
Potential Advantages
Why GLIA Is Investigating miRNA Biomarkers
Stability in Blood
Encapsulated in exosomes and bound to RNA-binding proteins, circulating miRNAs may resist degradation by RNases in blood. Temporal profiles vary by the individual miRNA, injury characteristics and sampling time — supporting potential utility across both acute and subacute assessment windows.
Brain-Tissue Association
Brain-enriched miRNAs are expressed at relatively low levels in peripheral tissues. Elevation in blood following head injury may therefore reflect neural or glial involvement rather than a non-specific response to systemic trauma.
Panel Approach
A panel of miRNAs may simultaneously provide information relevant to injury response and biological recovery in a single assay — potentially offering complementary information to any single protein biomarker. Claims regarding anatomical localisation or cellular subtype discrimination require further validation.
Potential Sensitivity in Mild TBI
GLIA’s research suggests the miRNA panel may detect molecular signals in mild TBI cases where CT and conventional MRI are normal. Further validation is required to establish clinical sensitivity and specificity.
Longitudinal Monitoring Potential
Serial miRNA measurements may track biological changes over time, potentially providing information relevant to recovery monitoring. These applications remain under development and require further clinical validation.
Point-of-Care Compatible
GLIA’s detection platform is being developed to quantify miRNA biomarkers from a finger-stick blood sample in field, sideline, and emergency department settings — without laboratory infrastructure.
Explore further
Related topics
TBI Biomarkers
The broader landscape of biomarkers and why molecular signals outperform protein-based tests.
Learn more →
GLIA NeuroTESTA
How miRNA science is packaged into a compact, field-ready diagnostic platform.
Learn more →
PTSD & TBI
Overlapping neurological signatures of TBI and PTSD — and why objective biomarkers matter.
Learn more →
Blast Overpressure
Invisible blast injuries and the need for molecular-level TBI detection.
Learn more →
Clinically Studied Proprietary miRNA Biomarkers
GLIA’s miRNA biomarker research is progressing toward a rapid, field-ready diagnostic platform. These uses remain under development and require further analytical and clinical validation. Explore the technology behind our GLIA NeuroTESTA platform.